

Long-term Outcome of 525 Patients With Mycosis Fungoides

Archives of Dermatology

139, 857-66

DOI: 10.1001/archderm.139.7.857

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cutaneous lymphoma. , 2001, , 233-251.		0
2	Mature T-Cell and NK-Cell Lymphomas in the Pediatric Age Group. Pathology Patterns Reviews, 2004, 122, S110-S121.	0.4	6
3	Transition of Sezary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis. Journal of Clinical Pathology, 2004, 57, 1325-1328.	1.0	9
4	The Pathogenesis of Mycosis Fungoides. New England Journal of Medicine, 2004, 350, 1978-1988.	13.9	338
5	Current management strategies for cutaneous T-cell lymphoma. Clinics in Dermatology, 2004, 22, 197-208.	0.8	45
6	Cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2004, 51, 43-45.	0.6	20
7	Clinical and Pathological Features of Posttransplantation Lymphoproliferative Disorders Presenting With Skin Involvement in 4 Patients. Archives of Dermatology, 2004, 140, 1140-6.	1.7	43
8	Analysis of T-Cell Receptor Gene Rearrangement for Predicting Clinical Outcome in Patients With Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2005, 141, 1107-13.	1.7	21
9	Mycosis fungoides - a retrospective study of 40 cases in Hong Kong. International Journal of Dermatology, 2005, 44, 215-220.	0.5	14
10	Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up. British Journal of Dermatology, 2005, 152, 1378-1379.	1.4	10
11	Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. British Journal of Dermatology, 2005, 153, 118-124.	1.4	57
12	Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. British Journal of Dermatology, 2005, 153, 324-330.	1.4	44
13	Beyond Clonal Detection. Archives of Dermatology, 2005, 141, 1159-60.	1.7	7
14	Classification of Primary Cutaneous Lymphomas. , 2005, 39, 25-37.		3
15	Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. European Journal of Haematology, 2005, 75, 136-145.	1.1	79
16	Pronostic des lymphomes T cutanÃ©s primitifs. Annales De Dermatologie Et De Venereologie, 2005, 132, 13-20.	0.5	5
17	Early TCR-Î² and TCR-Î³ PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood, 2005, 105, 503-510.	0.6	90
18	WHO-EORTC classification for cutaneous lymphomas. Blood, 2005, 105, 3768-3785.	0.6	3,529

#	ARTICLE	IF	CITATIONS
19	Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 242-246.	0.6	63
20	Association of change in clinical status and change in the percentage of the CD4+CD26 ⁺ lymphocyte population in patients with S�zary syndrome. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 428-434.	0.6	27
21	Bexarotene and systemic disease progression in CTCL?. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 365-366.	0.6	5
22	Retrospective 5-year review of 131 patients with mycosis fungoides and S�zary syndrome seen at the National Skin Centre, Singapore. <i>Australasian Journal of Dermatology</i> , 2006, 47, 248-252.	0.4	52
23	UVB in the management of early stage mycosis fungoides. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 565-572.	1.3	55
24	Mycosis fungoides associated with B-cell malignancies. <i>British Journal of Dermatology</i> , 2006, 155, 379-386.	1.4	66
25	Mycosis fungoides/Sezary syndrome: report of an unusual case. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 12-15.	0.7	9
26	Primary Cutaneous Lymphomas. , 2006, , 424-436.		0
27	Mycosis Fungoides in Childhood: Description and Study of Two Siblings. <i>Acta Dermato-Venereologica</i> , 2007, 87, 529-532.	0.6	12
28	Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3109-3115.	0.8	972
29	Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/S�zary Syndrome. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 836-840.	0.7	33
30	Second Lymphomas and Other Malignant Neoplasms in Patients With Mycosis Fungoides and S�zary Syndrome. <i>Archives of Dermatology</i> , 2007, 143, 45-50.	1.7	88
31	TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S�zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 479-484.	0.6	452
32	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. <i>Blood</i> , 2007, 110, 3015-3027.	0.6	115
33	The Diagnosis, Staging, and Treatment Options for Mycosis Fungoides. <i>Cancer Control</i> , 2007, 14, 102-111.	0.7	55
34	Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.. <i>Human Pathology</i> , 2007, 38, 462-467.	1.1	42
35	Absence of Microsatellite Instability and Lack of Evidence for Subclone Diversification in the Pathogenesis and Progression of Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1752-1761.	0.3	9
36	Revisions to the staging and classification of mycosis fungoides and S�zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). <i>Blood</i> , 2007, 110, 1713-1722.	0.6	1,243

#	ARTICLE	IF	CITATIONS
37	Cutaneous T-Cell Lymphoma: Overview and Nursing Perspectives. <i>Nursing Clinics of North America</i> , 2007, 42, 421-455.	0.7	7
38	Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides?. <i>British Journal of Dermatology</i> , 2007, 156, 57-61.	1.4	26
39	The optimal use of bexarotene in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2007, 157, 433-440.	1.4	150
40	Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2007, 23, 163-171.	0.7	32
41	Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). <i>JDDG - Journal of the German Society of Dermatology</i> , 2007, 5, 662-668.	0.4	95
42	Mycosis Fungoides: Pathophysiology and Emerging Therapies. <i>Seminars in Oncology</i> , 2007, 34, S21-S28.	0.8	37
43	Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome. <i>Cancer</i> , 2008, 114, 323-332.	2.0	20
44	A Prospective, Open-Label Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1204-1207.	0.4	37
45	Novel Therapies for Cutaneous T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S187-S192.	1.4	28
46	Cutaneous T-cell lymphoma and emerging therapies. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e69-e79.	0.8	0
47	Total skin electron beam therapy may be associated with improvement of peripheral blood disease in SÅ©zary syndrome. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 592-595.	0.6	38
48	Stem cell transplantation in advanced cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 645-649.	0.6	32
49	Mycosis fungoides and SÅ©zary syndrome. <i>Lancet, The</i> , 2008, 371, 945-957.	6.3	250
50	Overview of Lymphoma Diagnosis and Management. <i>Radiologic Clinics of North America</i> , 2008, 46, 175-198.	0.9	116
51	Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?. <i>Leukemia and Lymphoma</i> , 2008, 49, 2022-2024.	0.6	4
52	Granulomatous Mycosis Fungoides and Granulomatous Slack Skin. <i>Archives of Dermatology</i> , 2008, 144, 1609-17.	1.7	158
53	Primary cutaneous lymphomas: A population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003. <i>Leukemia and Lymphoma</i> , 2008, 49, 1537-1544.	0.6	26
54	Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. <i>Blood</i> , 2008, 112, 3082-3087.	0.6	160

#	ARTICLE	IF	CITATIONS
55	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 717.	3.0	35
56	Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. <i>Leukemia and Lymphoma</i> , 2009, 50, 1969-1976.	0.6	102
57	Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. <i>International Journal of Dermatology</i> , 2009, 48, 243-252.	0.5	108
58	Bexarotene therapy for mycosis fungoides and SÅ©zary syndrome. <i>British Journal of Dermatology</i> , 2009, 160, 1299-1307.	1.4	96
59	Controversies in the management of the cutaneous T cell lymphomas. <i>Dermatologic Therapy</i> , 2009, 22, 407-417.	0.8	8
60	A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and SÅ©zary Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 982-990.	2.0	108
63	Low-Dose Gemcitabine Efficacious in Three Patients With Tumor-Stage Mycosis Fungoides. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, E21-E24.	1.4	8
64	Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 412-416.	1.4	88
65	CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1860-1868.	2.1	100
66	The Development of Two Educational Manuals for Patients, Doctors, and Nurses Dealing With Cutaneous T-Cell Lymphoma. <i>Journal of the Dermatology Nurses' Association</i> , 2009, 1, 147.	0.1	0
67	Oncogenomic analysis of mycosis fungoides reveals major differences with SÅ©zary syndrome. <i>Blood</i> , 2009, 113, 127-136.	0.6	188
68	How I treat mycosis fungoides and SÅ©zary syndrome. <i>Blood</i> , 2009, 114, 4337-4353.	0.6	144
69	Update on treatment of cutaneous T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2009, 21, 131-137.	1.1	35
70	CD4+, CD56+ Mycosis Fungoides: Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2009, 31, 74-76.	0.3	17
71	SÅ©zary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. <i>Blood</i> , 2010, 116, 767-771.	0.6	440
72	B-cell Lymphofollicular Infiltrates in Mycosis Fungoides. <i>Tumori</i> , 2010, 96, 487-491.	0.6	11
73	Targeted treatment and new agents in peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 33-44.	0.7	26
74	Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and) Tj ETQq1 1 0.784314 rgBT /Over <i>Pharmacology</i> , 2010, 80, 1650-1661.	2.0	17

#	ARTICLE	IF	CITATIONS
75	Hypopigmented Macules and Patches on the Extremities of a Teenager. <i>Pediatric Dermatology</i> , 2010, 27, 197-198.	0.5	0
76	Somatostatin receptor scintigraphy in primary cutaneous T&B cell lymphomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 13-17.	1.3	7
77	Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991"2006. <i>International Journal of Dermatology</i> , 2010, 49, 1393-1398.	0.5	41
78	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T&cell and natural killer&cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	1.2	44
79	Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. <i>Core Evidence</i> , 2010, 6, 1.	4.7	9
80	Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. <i>Cancer Management and Research</i> , 2010, 2, 53.	0.9	37
81	Skin-Resident T Cells: The Ups and Downs of On Site Immunity. <i>Journal of Investigative Dermatology</i> , 2010, 130, 362-370.	0.3	239
82	Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 2106-2114.	3.2	76
83	Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3073-3084.	0.9	7
84	Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and S&ary Syndrome. <i>Journal of Clinical Oncology</i> , 2010, 28, 2365-2372.	0.8	149
85	Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1707-1718.	0.3	100
86	Curcumin Selectively Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines and Patients&TM PBMCs: Potential Role for STAT-3 and NF&B Signaling. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2110-2119.	0.3	96
87	Evolution of Clinical and Molecular Responses to Bexarotene Treatment in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2010, 220, 370-375.	0.9	19
88	Flow cytometric detection of peripheral blood involvement by mycosis fungoides and S&ary syndrome using T-cell receptor V&2 chain antibodies and its application in blood staging. <i>Modern Pathology</i> , 2010, 23, 284-295.	2.9	58
89	Prognosis of 100 Japanese patients with mycosis fungoides and S&ary syndrome. <i>Journal of Dermatological Science</i> , 2010, 57, 37-43.	1.0	42
90	A Look at the National Comprehensive Cancer Network Guidelines for Cutaneous Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, S109-S111.	0.2	2
91	Cutaneous T-cell Lymphomas. , 2010, , 427-447.		3
92	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 975-983.	0.6	90

#	ARTICLE	IF	CITATIONS
93	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	0.8	604
94	Survival Outcomes and Prognostic Factors in Mycosis Fungoides/S�azary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal. <i>Journal of Clinical Oncology</i> , 2010, 28, 4730-4739.	0.8	675
95	Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1870-1877.	0.8	212
97	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011, 52, 1463-1473.	0.6	37
98	Erythrodermic cutaneous T-cell lymphoma: How to differentiate this rare disease from atopic dermatitis. <i>Journal of Dermatological Science</i> , 2011, 64, 1-6.	1.0	53
99	Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark. <i>Acta Oncol�gica</i> , 2011, 50, 1199-1205.	0.8	27
100	Psoralen plus ultraviolet A�light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 212-214.	0.6	7
101	S�azary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 352-404.	0.6	154
102	Revisiting Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e651-e657.	0.4	89
103	Small Bowel Obstruction Due to Mycosis Fungoides: An Unusual Presentation. <i>American Journal of the Medical Sciences</i> , 2011, 341, 508-509.	0.4	13
104	Cutaneous T-Cell Lymphoma. <i>Journal of the Dermatology Nurses' Association</i> , 2011, 3, 75-83.	0.1	2
105	High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. <i>Blood</i> , 2011, 117, 1966-1976.	0.6	55
106	Is PUVA maintenance therapy necessary in patients with early�stage mycosis fungoides? Evaluation of a treatment guideline over a 28�month follow�up. <i>International Journal of Dermatology</i> , 2011, 50, 1086-1093.	0.5	13
107	Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. <i>Journal of Dermatology</i> , 2011, 38, 524-530.	0.6	42
108	Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2011, 164, 814-821.	1.4	11
109	Evolving Insights in the Pathogenesis and Therapy of Cutaneous T�cell lymphoma (Mycosis Fungoides) Tj ETQq1 1,0,784314,rgBT /Ove 1.2 127	1.0	127
110	Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. <i>Journal of Antibiotics</i> , 2011, 64, 525-531.	1.0	251
111	Tratamiento de linfomas cut�neos de c�lulas T con fotoimmunoterapia extracorp�rea (Fotof�resis). <i>Piel</i> , 2011, 26, 523-531.	0.0	0

#	ARTICLE	IF	CITATIONS
112	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 627-630.	2.0	10
113	Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2011, 86, 610-611.	2.0	80
114	Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 928-948.	2.0	61
115	The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides. <i>Archives of Dermatology</i> , 2011, 147, 561.	1.7	102
116	Cutaneous T-Cell Lymphoma. <i>Journal of the Dermatology Nurses' Association</i> , 2011, 3, 18-32.	0.1	0
117	Clinical End Points and Response Criteria in Mycosis Fungoides and S�zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
118	Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2451-2461.	1.9	68
119	Photopheresis in the treatment of cutaneous T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2012, 24, S1-S10.	1.1	20
120	Primary cutaneous T-cell lymphomas. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2012, 9, 1-13.	0.2	1
121	Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 868-877.	0.6	8
122	Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. <i>Bone Marrow Transplantation</i> , 2012, 47, 65-72.	1.3	50
123	Regulatory T cells and immunodeficiency in mycosis fungoides and S�zary syndrome. <i>Leukemia</i> , 2012, 26, 424-432.	3.3	105
124	Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. <i>Science Translational Medicine</i> , 2012, 4, 117ra7.	5.8	312
125	Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs. <i>Molecular Pharmacology</i> , 2012, 82, 938-947.	1.0	26
126	Management of cutaneous T-cell lymphoma. <i>Clinical Medicine</i> , 2012, 12, 160-164.	0.8	5
127	Immunophenotypic Stability of S�zary Cells by Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2012, 137, 403-411.	0.4	22
128	Adverse Effects of Denileukin Diftitox and Their Management in Patients With Cutaneous T-Cell Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, E164-E172.	0.3	21
129	Large Cell Transformation of Mycosis Fungoides on Fine Needle Aspiration: An Unusual Case Mimicking Classical Hodgkin Lymphoma. <i>Acta Cytologica</i> , 2012, 56, 321-324.	0.7	3

#	ARTICLE	IF	CITATIONS
130	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2012, 119, 4115-4122.	0.6	122
131	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2012, 28, 250-257.	0.7	41
132	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma		

#	ARTICLE	IF	CITATIONS
148	Romidepsin: A New Drug for the Treatment of Cutaneous T-Cell Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, 195-204.	0.3	36
149	Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. <i>Cancer Management and Research</i> , 2012, 4, 75.	0.9	35
150	Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides. <i>Cancer</i> , 2012, 118, 5830-5839.	2.0	105
151	Mycosis fungoides with testicular involvement: A rare phenomenon. <i>Leukemia Research</i> , 2012, 36, e149-e152.	0.4	1
152	Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. <i>Journal of Dermatology</i> , 2012, 39, 823-828.	0.6	21
153	Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. <i>British Journal of Dermatology</i> , 2012, 166, 1295-1300.	1.4	11
154	A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. <i>International Journal of Hematology</i> , 2012, 95, 217-222.	0.7	8
155	Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2013, 139, 466-490.	0.4	60
156	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. <i>European Journal of Cancer</i> , 2013, 49, 2859-2868.	1.3	121
157	Prognostic factors in 105 Japanese cases of mycosis fungoides and Sezary syndrome: Clusterin expression as a novel prognostic factor. <i>Journal of Dermatological Science</i> , 2013, 71, 160-166.	1.0	20
158	Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 377-384.	0.2	35
159	Prevalence and Severity of Pruritus and Quality of Life in Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 114-119.	0.6	74
160	Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. <i>Science Translational Medicine</i> , 2013, 5, 214ra171.	5.8	84
162	Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children. <i>Current Dermatology Reports</i> , 2013, 2, 203-211.	1.1	6
163	Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. <i>International Journal of Hematology</i> , 2013, 98, 491-495.	0.7	7
164	Update on Epidemiology of Cutaneous T-Cell Lymphoma. <i>Current Dermatology Reports</i> , 2013, 2, 35-41.	1.1	5
165	Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: A prospective open study and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 890-897.	0.6	43
166	Proteasome inhibition as a novel mechanism of the proapoptotic activity of β 3-secretase inhibitor I in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013, 168, 504-512.	1.4	14

#	ARTICLE	IF	CITATIONS
167	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. <i>Leukemia and Lymphoma</i> , 2013, 54, 284-289.	0.6	36
168	Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Dermatological Association. <i>Journal of Dermatology</i> , 2013, 40, 2-14.	0.6	36
169	Was Treatment the Trigger? Mycosis Fungoides. <i>American Journal of Medicine</i> , 2013, 126, 1048-1049.	0.6	6
170	Cutaneous tumor cell load correlates with survival in patients with Sézary syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 67-79.	0.4	8
171	Topical Chemotherapy in Cutaneous T-cell Lymphoma. <i>JAMA Dermatology</i> , 2013, 149, 25.	2.0	147
172	Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 21-31.	2.0	31
173	Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. <i>Leukemia and Lymphoma</i> , 2013, 54, 752-759.	0.6	98
174	Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 653-654.	0.6	20
175	Romidepsin for the treatment of T-cell lymphomas. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1115-1122.	0.5	27
176	Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/sezary syndrome. <i>British Journal of Haematology</i> , 2013, 162, 130-132.	1.2	6
177	Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013, 169, 1188-1197.	1.4	43
178	Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. <i>Blood</i> , 2013, 122, 943-950.	0.6	78
179	Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. <i>Blood</i> , 2013, 122, 2539-2549.	0.6	661
181	Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. <i>The Cochrane Library</i> , 2013, , CD008908.	1.5	13
182	Aggressive worsening of Sézary syndrome during early antiretroviral therapy. <i>Aids</i> , 2013, 27, 1035-1036.	1.0	2
183	Allogeneic hematopoietic stem cell transplantation in mycosis fungoides. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 216-219.	0.5	0
184	Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. <i>Journal of Clinical Pathology</i> , 2014, 67, 431-436.	1.0	21
185	Concurrent chronic lymphocytic leukemia and cutaneous T cell lymphoma: a case series. <i>Leukemia and Lymphoma</i> , 2014, 55, 2192-2195.	0.6	1

#	ARTICLE	IF	CITATIONS
186	Mycosis Fungoides, 2014, .		0
187	Cutaneous T-cell lymphomas and their management strategies. Indian Journal of Cancer, 2014, 51, 293.	0.2	3
188	Are we close to a prognostic index for cutaneous T cell lymphoma?. Leukemia and Lymphoma, 2014, 55, 7-8.	0.6	3
189	Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs, 2014, 2, 625-634.	0.5	3
190	Immunogenetic factors in mycosis fungoides: can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1732-1737.	1.3	10
191	Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides. British Journal of Dermatology, 2014, 170, 1080-1086.	1.4	5
192	Pediatric Mycosis Fungoides in Singapore: A Series of 46 Children. Pediatric Dermatology, 2014, 31, 477-482.	0.5	40
193	Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology, 2014, 7, 481-493.	1.0	6
194	Outcomes After Diagnosis of Mycosis Fungoides and Sezary Syndrome Before 30 Years of Age. JAMA Dermatology, 2014, 150, 709.	2.0	26
195	The Influence of the Coexpression of CD4 and CD8 in Cutaneous Lesions on Prognosis of Mycosis Fungoides: A Preliminary Study. Journal of Skin Cancer, 2014, 2014, 1-4.	0.5	7
196	Characteristics of Primary Cutaneous T-Cell Lymphoma in Iran: A 10-Year Retrospective Study. International Scholarly Research Notices, 2014, 2014, 1-5.	0.9	4
197	Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study. Journal of the American Academy of Dermatology, 2014, 71, 529-535.	0.6	24
198	Prognostic factors and risk stratification in early mycosis fungoides. Leukemia and Lymphoma, 2014, 55, 44-50.	0.6	23
199	Lymph node fine needle Cytology in the staging and follow-up of Cutaneous Lymphomas. BMC Cancer, 2014, 14, 8.	1.1	30
200	Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. Journal of Photochemistry and Photobiology B: Biology, 2014, 131, 104-112.	1.7	14
201	Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leukemia Research, 2014, 38, 49-56.	0.4	22
203	Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review. British Journal of Dermatology, 2014, 170, 1015-1020.	1.4	5
204	Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults. Reports of Practical Oncology and Radiotherapy, 2014, 19, 92-98.	0.3	19

#	ARTICLE	IF	CITATIONS
205	The current management of mycosis fungoides and S�azary syndrome and the role of radiotherapy: Principles and indications. Reports of Practical Oncology and Radiotherapy, 2014, 19, 77-91.	0.3	20
206	Clinical results of the total skin electron irradiation of the mycosis fungoides in adults. Conventional fractionation and low dose schemes. Reports of Practical Oncology and Radiotherapy, 2014, 19, 99-103.	0.3	11
207	Primary cutaneous T-cell lymphoma (mycosis fungoides and S�azary syndrome). Journal of the American Academy of Dermatology, 2014, 70, 223.e1-223.e17.	0.6	249
208	Primary cutaneous T-cell lymphoma (mycosis fungoides and S�azary syndrome). Journal of the American Academy of Dermatology, 2014, 70, 205.e1-205.e16.	0.6	287
209	A Review of Survival in Mycosis Fungoides. American Journal of Clinical Pathology, 2014, 141, 706-711.	0.4	9
210	Mycosis fungoides in a referral center in central Taiwan: A retrospective case series and literature review. Dermatologica Sinica, 2014, 32, 148-153.	0.2	5
211	Cutaneous T�cell lymphoma: 2014 Update on diagnosis, risk�stratification, and management. American Journal of Hematology, 2014, 89, 837-851.	2.0	58
213	Systematic review of combination therapies for mycosis fungoides. Cancer Treatment Reviews, 2014, 40, 927-933.	3.4	41
214	Prognostic factors, prognostic indices and staging in mycosis fungoides and S�azary syndrome: where are we now?. British Journal of Dermatology, 2014, 170, 1226-1236.	1.4	121
215	Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2014, 32, 1157-1163.	0.8	309
216	Cutaneous lymphoma in Japan: A nationwide study of 1733 patients. Journal of Dermatology, 2014, 41, 3-10.	0.6	61
217	Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 297-304.	0.2	16
218	Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced Stages. Seminars in Hematology, 2014, 51, 35-41.	1.8	6
219	S�azary Syndrome. Surgical Pathology Clinics, 2014, 7, 191-202.	0.7	4
220	Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany). Phytochemistry Reviews, 2014, 13, 459-469.	3.1	7
221	A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Baz�n type) mycosis fungoides. British Journal of Dermatology, 2014, 170, 1266-1275.	1.4	21
222	Mycosis Fungoides. Surgical Pathology Clinics, 2014, 7, 143-167.	0.7	8
223	Recent clinical evidence for topical mechlorethamine in mycosis fungoides. Clinical Investigation, 2014, 4, 745-761.	0.0	3

#	ARTICLE	IF	CITATIONS
224	Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and SÅ©zary syndrome. Hematology American Society of Hematology Education Program, 2015, 2015, 529-544.	0.9	14
225	Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood, 2015, 126, 1452-1461.	0.6	174
226	Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood, 2015, 125, 2798-2805.	0.6	118
227	Expression of special AT-rich sequence-binding protein 1 is an independent prognostic factor in cutaneous T-cell lymphoma. Oncology Reports, 2015, 33, 250-266.	1.2	14
228	Treatment of localized mycosis fungoides with digital <sc>UV</sc> photochemotherapy. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 333-340.	0.7	2
229	Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. British Journal of Dermatology, 2015, 173, 1295-1297.	1.4	20
230	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. British Journal of Dermatology, 2015, 173, 1015-1023.	1.4	11
231	Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1696-1709.	1.3	50
232	Frequency of primary cutaneous lymphoma variants in Austria: retrospective data from a dermatology referral centre between 2006 and 2013. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1517-1523.	1.3	14
233	Mycosis Fungoides, Then and Nowâ€¦ Have We Travelled?. Advances in Anatomic Pathology, 2015, 22, 376-383.	2.4	2
234	Rapidly progressive stage IVB mycosis fungoides treated with low-dose total skin electron beam therapy. OncoTargets and Therapy, 2015, 8, 1597.	1.0	6
235	Mycosis Fungoides in Iranian Population: An Epidemiological and Clinicopathological Study. Journal of Skin Cancer, 2015, 2015, 1-6.	0.5	11
236	Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team. British Journal of Dermatology, 2015, 173, 1081-1083.	1.4	8
237	Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy. Current Hematologic Malignancy Reports, 2015, 10, 468-476.	1.2	27
238	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology, 2015, 72, 286-292.	0.6	156
239	Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and SÅ©zary syndrome in the southeastern United States: A single-institution cohort. Journal of the American Academy of Dermatology, 2015, 72, 276-285.	0.6	52
240	Cutaneous T-Cell Lymphoma. , 2015, , 363-377.		0
241	Resident memory T cells in human health and disease. Science Translational Medicine, 2015, 7, 269rv1.	5.8	347

#	ARTICLE	IF	CITATIONS
242	Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. <i>Hematology</i> , 2015, 20, 538-542.	0.7	25
243	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. <i>Blood</i> , 2015, 126, 508-519.	0.6	193
244	Vorinostat for Refractory or Relapsing Epidermotropic T-cell Lymphoma: A Retrospective Cohort Study of 15 Patients. <i>Acta Dermato-Venereologica</i> , 2015, 95, 72-77.	0.6	13
245	Delay in the Histopathologic Diagnosis of Mycosis Fungoides. <i>Acta Dermato-Venereologica</i> , 2015, 95, 472-475.	0.6	16
246	Advanced-Stage Mycosis Fungoides and SÃ©zary Syndrome: Survival and Response to Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e105-e112.	0.2	35
247	Alarms and Parameters Generated by Hematology Analyzer: New Tools to Predict and Quantify Circulating Sezary Cells. <i>Journal of Clinical Laboratory Analysis</i> , 2015, 29, 153-161.	0.9	8
248	Granulomatous mycosis fungoides: A 3-year follow-up of a case. <i>Dermatologica Sinica</i> , 2015, 33, 245-246.	0.2	1
249	Hematopoietic Stem Cell Transplant for Mycosis Fungoides and SÃ©zary Syndrome. <i>Dermatologic Clinics</i> , 2015, 33, 807-818.	1.0	39
250	Monoclonal Antibodies. <i>Dermatologic Clinics</i> , 2015, 33, 777-786.	1.0	19
251	SÃ©zary Syndrome. , 2015, , 61-71.		0
252	TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. <i>Science Translational Medicine</i> , 2015, 7, 308ra158.	5.8	171
253	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÃ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
254	Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma. <i>Dermatologic Clinics</i> , 2015, 33, 787-805.	1.0	4
255	Skin-Directed Therapies in Cutaneous T-Cell Lymphoma. <i>Dermatologic Clinics</i> , 2015, 33, 683-696.	1.0	10
256	Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1077-1086.	0.4	65
257	Genomic profiling of SÃ©zary syndrome identifies alterations of key T cell signaling and differentiation genes. <i>Nature Genetics</i> , 2015, 47, 1426-1434.	9.4	276
258	Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. <i>Hematological Oncology</i> , 2016, 34, 9-16.	0.8	22
259	Experimental treatment strategies in primary cutaneous T-cell lymphomas. <i>Current Opinion in Oncology</i> , 2016, 28, 166-171.	1.1	6

#	ARTICLE	IF	CITATIONS
260	Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers. <i>Australasian Journal of Dermatology</i> , 2016, 57, 182-191.	0.4	18
261	The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. <i>British Journal of Dermatology</i> , 2016, 175, 794-796.	1.4	12
262	Lymph Node Fine-Needle Cytology of Non-Hodgkin Lymphoma: Diagnosis and Classification by Flow Cytometry. <i>Acta Cytologica</i> , 2016, 60, 302-314.	0.7	42
263	Primary Cutaneous Lymphomas. , 2016, , 257-263.		0
264	How I treat mycosis fungoides and Sézary syndrome. <i>Blood</i> , 2016, 127, 3142-3153.	0.6	138
265	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. <i>Blood</i> , 2016, 127, 1287-1296.	0.6	86
266	TOX expression and role in CTCL. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1497-1502.	1.3	26
267	Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. <i>Journal of Dermatological Science</i> , 2016, 84, 239-247.	1.0	16
268	Sézary Syndrome: Clinical and Biological Aspects. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 468-479.	1.2	17
269	Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 151-165.	2.0	118
270	Cutaneous lymphoma: Kids are not just little people. <i>Clinics in Dermatology</i> , 2016, 34, 749-759.	0.8	23
271	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S181-S190.e4.	0.2	7
272	A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sézary syndrome. <i>American Journal of Hematology</i> , 2016, 91, E491-E495.	2.0	41
274	Mogamulizumab in the treatment of cutaneous T cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1277-1280.	0.5	0
275	Paraneoplastic Dermatitis in a Patient with Anaplastic Large-Cell Lymphoma: Case Report and Literature Review. <i>Dermatopathology (Basel, Switzerland)</i> , 2016, 3, 39-43.	0.7	3
276	Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. <i>JAMA Dermatology</i> , 2016, 152, 992.	2.0	119
277	Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 1060-1066.	0.6	9
278	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 228-240.	2.0	29

#	ARTICLE	IF	CITATIONS
279	Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-V β 2 chain restriction. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 870-877.	0.6	36
280	Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 225-237.	3.3	24
281	Guidelines for phototherapy of mycosis fungoides and S \odot zary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 27-58.	0.6	138
282	Mycosis Fungoides of the Rectum: Case Report and Review of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 417-419.	0.6	3
283	Mycosis fungoides: association of <scp>KIR</scp> ligands and <scp>HLA</scp>â€<scp>DQB</scp>1*05 with bad prognosis of the disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 266-269.	1.3	5
284	Alemtuzumab treatment for S \odot zary syndrome: A single-center experience. <i>Journal of Dermatological Treatment</i> , 2016, 27, 179-181.	1.1	6
285	Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 292-301.	0.5	13
286	Gain of CD26 expression on the malignant T ϵ cells in relapsed erythrodermic leukemic mycosis fungoides. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 462-466.	0.7	2
287	Increased Expression of PLS3 Correlates with Better Outcome in S \odot zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2017, 137, 754-757.	0.3	7
288	Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. <i>International Journal of Women's Dermatology</i> , 2017, 3, 100-106.	1.1	22
290	Comprehensive analysis of cutaneous T ϵ cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. <i>Cancer</i> , 2017, 123, 3550-3567.	2.0	70
291	Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and S \odot zary Syndrome. <i>Journal of Neuro-Oncology</i> , 2017, 132, 439-446.	1.4	33
292	Cutaneous T-Cell Lymphoma. , 2017, , 715-740.		1
293	The biomarker landscape in mycosis fungoides and S \odot zary syndrome. <i>Experimental Dermatology</i> , 2017, 26, 668-676.	1.4	26
294	Cutaneous Lymphomaâ€”Inpatient Considerations. <i>Current Dermatology Reports</i> , 2017, 6, 63-76.	1.1	0
295	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\gamma\delta$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous β 1 T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 204-215.	2.1	57
296	Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 170-172.	0.3	1
297	Multidisciplinary Management of Mycosis Fungoides/S \odot zary Syndrome. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 234-243.	1.2	10

#	ARTICLE	IF	CITATIONS
298	Atom and receptor based 3D QSAR models for generating new conformations from pyrazolopyrimidine as IL-2 inducible tyrosine kinase inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 74, 379-395.	1.3	6
299	S�zary syndrome without erythroderma: A review of 16 cases at Mayo Clinic. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 683-688.	0.6	15
300	Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. <i>Expert Review of Hematology</i> , 2017, 10, 111-121.	1.0	13
301	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
302	Cutaneous T�cell lymphoma: 2017 update on diagnosis, risk�stratification, and management. <i>American Journal of Hematology</i> , 2017, 92, 1085-1102.	2.0	104
303	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2304-2314.	1.9	10
304	Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. <i>Blood Cancer Journal</i> , 2017, 7, e517-e517.	2.8	24
305	Brentuximab vedotin in CD30⁺ primary cutaneous T�cell lymphomas: a review and analysis of existing data. <i>International Journal of Dermatology</i> , 2017, 56, 1400-1405.	0.5	11
306	Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 497-502.e2.	0.6	54
307	Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 604-612.	0.2	9
308	CD8 + mycosis fungoides: A low-grade lymphoproliferative disorder. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 489-496.	0.6	31
309	Prognostic indicators for mycosis fungoides in a Greek population. <i>British Journal of Dermatology</i> , 2017, 176, 1321-1330.	1.4	25
310	Epidemiological and clinical features of patients diagnosed with cutaneous T�cell lymphomas in a Spanish tertiary care hospital. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e150-e153.	1.3	2
311	T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. <i>Korean Journal of Radiology</i> , 2017, 18, 71.	1.5	14
312	Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. <i>PLoS ONE</i> , 2017, 12, e0170186.	1.1	5
313	Psoriasiform mycosis fungoides masquerading as tumorous plaques. <i>European Journal of Dermatology</i> , 2017, 27, 295-296.	0.3	4
314	Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 649-654.	0.5	6
315	What Is New in CTCL�Pathogenesis, Diagnosis, and Treatments. <i>Current Dermatology Reports</i> , 2018, 7, 91-98.	1.1	4

#	ARTICLE	IF	CITATIONS
316	Clinically defined subgroups of mycosis fungoides display differing histopathological features at initial biopsy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2871-2879.	0.6	2
317	Distribution and Clustering of Cutaneous T-Cell Lymphoma (CTCL) Cases in Canada During 1992 to 2010. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 154-165.	0.6	42
318	Registro de linfomas cutáneos primarios de la AEDV: primer año de funcionamiento. <i>Actas Dermo-sifilográficas</i> , 2018, 109, 610-616.	0.2	13
319	Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. <i>Current Oncology Reports</i> , 2018, 20, 32.	1.8	31
320	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 726-734.	2.1	17
321	Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. <i>Experimental Dermatology</i> , 2018, 27, 188-190.	1.4	8
322	An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. <i>Journal of Dermatological Treatment</i> , 2018, 29, 522-530.	1.1	13
323	Gradually Worsening Pruritic Plaques. <i>JAMA Oncology</i> , 2018, 4, 573.	3.4	1
324	The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. <i>Journal of Dermatological Treatment</i> , 2018, 29, 272-276.	1.1	15
325	Hypopigmented Interface T-Cell Dyscrasia and Hypopigmented Mycosis Fungoides: A Comparative Study. <i>American Journal of Dermatopathology</i> , 2018, 40, 727-735.	0.3	3
326	Mature T-Cell and Natural Killer Cell Leukemias. , 2018, , 414-428.e1.		1
327	Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 680-685.	0.5	5
328	Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 805-819.	3.3	38
329	Cutaneous Lymphomas. , 2018, , 155-187.		0
330	Cutaneous Lymphomas. , 2018, , 769-780.		0
331	Sézary Syndrome Presenting With Renal Involvement. <i>American Journal of Kidney Diseases</i> , 2018, 72, 890-894.	2.1	0
332	Clinical and epidemiological profile of patients with early stage mycosis fungoides. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 546-552.	0.5	23
333	IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 691-697.	1.9	12

#	ARTICLE	IF	CITATIONS
334	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. <i>Actas Dermo-sifiliogrficas</i> , 2018, 109, 610-616.	0.2	3
335	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Biomarker in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2388-2397.	0.3	15
336	Infectious events and associated risk factors in mycosis fungoides/Szary syndrome: a retrospective cohort study. <i>British Journal of Dermatology</i> , 2018, 179, 1322-1328.	1.4	31
337	Integrating novel systemic therapies for the treatment of mycosis fungoides and Szary syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 322-335.	0.7	8
338	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398
339	Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides. <i>Medicine (United States)</i> , 2018, 97, e10871.	0.4	7
340	Cutaneous Lymphomas. <i>Clinical Oncology</i> , 2019, 31, 797-807.	0.6	7
341	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. <i>Blood</i> , 2019, 134, 1072-1083.	0.6	94
342	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , 2019, 110, 406-410.	0.7	4
343	Mycosis fungoides and Szary syndrome: 2019 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019, 94, 1027-1041.	2.0	77
344	Overview of Cutaneous T-Cell Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 669-686.	0.9	8
345	Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. <i>Frontiers in Oncology</i> , 2019, 9, 645.	1.3	8
346	STAT3 Dysregulation in Mature T and NK Cell Lymphomas. <i>Cancers</i> , 2019, 11, 1711.	1.7	23
347	Durable Control of Mycosis Fungoides after Sepsis: "Coley"™s Toxin? Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.3	0
348	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. <i>Radiotherapy and Oncology</i> , 2019, 131, 88-92.	0.3	6
349	Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). <i>Frontiers in Oncology</i> , 2019, 9, 300.	1.3	47
350	Potential of narrow-band ultraviolet B to induce sustained durable complete remission off-therapy in patients with stage I mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1550-1555.	0.6	10
351	CD4/CD8 Double-negative Mycosis Fungoides: A Case Report and Literature Review. <i>Yonago Acta Medica</i> , 2019, 62, 153-158.	0.3	14

#	ARTICLE	IF	CITATIONS
352	Epidemiology and prognostic factors for mycosis fungoides and SÅ©zary syndrome in a multi-ethnic Asian cohort: a 12-year review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1513-1521.	1.3	16
353	Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients. <i>International Journal of Dermatology</i> , 2019, 58, 933-939.	0.5	6
354	Targeting CD47 in SÅ©zary syndrome with SIRPÎ±Fc. <i>Blood Advances</i> , 2019, 3, 1145-1153.	2.5	77
355	Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with SÅ©zary syndrome. <i>Blood</i> , 2019, 134, 1346-1350.	0.6	29
356	Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. <i>Journal of the National Medical Association</i> , 2019, 111, 633-639.	0.6	17
357	Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and SÅ©zary syndrome: a retrospective analysis of 174 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 108-114.	1.3	14
358	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. <i>British Journal of Dermatology</i> , 2019, 180, 496-526.	1.4	111
359	Clinical application of Total Skin Electron Beam (TSEB) therapy for the management of T cell cutaneous lymphomas. The evolving role of low dose (12 Gy) treatment schedule. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 26-30.	0.9	8
360	Total Skin Electron Beam Therapy for Mycosis Fungoides Revisited With Adjuvant Systemic Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 83-88.	0.2	7
361	Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. <i>British Journal of Dermatology</i> , 2019, 181, 1296-1302.	1.4	9
362	Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 33-43.	0.7	10
363	Brentuximab vedotin in T-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 5-19.	1.0	18
364	Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 485-492.e4.	0.6	7
365	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.4	127
366	Dramatic response to brentuximab vedotin in refractory nontransformed CD30 ⁺ mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission. <i>British Journal of Dermatology</i> , 2019, 180, 1517-1520.	1.4	16
367	Characteristics associated with significantly worse quality of life in mycosis fungoides/SÅ©zary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PCLIP) Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 25, 1070-1075.	1.0	10
368	Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. <i>Journal of Dermatological Treatment</i> , 2020, 31, 91-98.	1.1	7
369	Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management. <i>Pediatric Dermatology</i> , 2020, 37, 18-28.	0.5	20

#	ARTICLE	IF	CITATIONS
370	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 76-82.	2.0	26
371	Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 495-497.e5.	0.3	43
372	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. , 2020, , 1948-1964.e5.		0
373	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. <i>Archives of Dermatological Research</i> , 2020, 312, 283-288.	1.1	18
374	Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK). <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111918.	2.6	7
375	<p>>Spotlight on Mogamulizumab-Kpcc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or SA&szly Syndrome: Efficacy, Safety, and Patient Selection<p>>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3747-3754.	2.0	6
376	Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma. <i>Biomaterials</i> , 2020, 262, 120338.	5.7	9
377	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. <i>Blood Advances</i> , 2020, 4, 4788-4797.	2.5	9
378	Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 2955-2961.	0.6	10
379	Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL). <i>Journal of Medical Economics</i> , 2020, 23, 1142-1150.	1.0	2
380	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4474-4482.	2.5	25
382	Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in SA&szly cells. <i>Biochemistry and Biophysics Reports</i> , 2020, 24, 100832.	0.7	12
384	Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas. <i>Dermatologic Therapy</i> , 2020, 33, e13478.	0.8	2
385	A Long-Term Study of Persistent SA&szly Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. <i>American Journal of Dermatopathology</i> , 2020, 42, 389-396.	0.3	0
386	Emerging Research in Chronic Pruritus: From Bedside to Bench and Back Again. <i>Medicines (Basel)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	2
387	Interventions for mycosis fungoides. <i>The Cochrane Library</i> , 2020, 7, CD008946.	1.5	12
388	Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: A possible new regimen for the treatment of advanced cutaneous T-cell lymphoma. <i>JAAD Case Reports</i> , 2020, 6, 581-583.	0.4	1
389	Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center. <i>Medicines (Basel)</i> , Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50		

#	ARTICLE	IF	CITATIONS
390	<p>Cost of early-stage mycosis fungoides treatments in Spain</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 91-105.	0.7	0
391	Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clinical Cancer Research, 2020, 26, 1000-1008.	3.2	26
392	Value of High-Frequency Ultrasound in Accurate Staging of Mycosis Fungoides/S�zary Syndrome. Journal of Ultrasound in Medicine, 2020, 39, 1927-1937.	0.8	11
393	Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clinical Cancer Research, 2020, 26, 408-418.	3.2	23
394	Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nature Communications, 2020, 11, 1806.	5.8	62
395	Cutaneous T-cell lymphoma of the eyelid masquerading as dermatitis. Orbit, 2021, 40, 75-78.	0.5	2
396	S�zary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping. Cytometry Part B - Clinical Cytometry, 2021, 100, 132-138.	0.7	24
397	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPi) international study*. British Journal of Dermatology, 2021, 184, 524-531.	1.4	18
398	Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K�/� and HDAC. Journal of Investigative Dermatology, 2021, 141, 364-373.	0.3	17
399	It is time to adopt a multicolor immunophenotyping approach to evaluate blood for S�zary syndrome and mycosis fungoides. Cytometry Part B - Clinical Cytometry, 2021, 100, 125-128.	0.7	8
400	The importance of assessing blood tumour burden in cutaneous T�cell lymphoma*. British Journal of Dermatology, 2021, 185, 19-25.	1.4	12
401	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/S�zary syndrome than quantification of <scp>CD26</scp>� or <scp>CD7</scp>� <scp>CD4</scp>+ T�cells. Cytometry Part B - Clinical Cytometry, 2021, 100, 183-191.	0.7	15
402	The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T�cell lymphoma. British Journal of Haematology, 2021, 192, 683-696.	1.2	24
403	Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. Journal of Dermatology, 2021, 48, e49-e71.	0.6	14
404	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 97-105.	0.2	18
405	Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort. JAMA Dermatology, 2021, 157, 157.	2.0	20
406	Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clinics in Dermatology, 2021, 39, 64-75.	0.8	2
407	Indolent and Aggressive Mature T-Cell and Natural Killer�Cell Lymphomas. , 2021, , 251-273.		0

#	ARTICLE	IF	CITATIONS
408	Indolent Cutaneous T-Cell Lymphomas. <i>Hematologic Malignancies</i> , 2021, , 209-230.	0.2	0
410	Clinical characteristics and outcomes of black patients with mycosis fungoides and SÅ©zary syndrome: a subgroup analysis of the phase III MAVORIC trial. <i>Leukemia and Lymphoma</i> , 2021, 62, 1877-1883.	0.6	10
411	Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for > 15 Years with Localised Electron Beam Therapy. <i>Case Reports in Dermatological Medicine</i> , 2021, 2021, 1-3.	0.1	0
412	Clinicoprognostic implications of head and neck involvement by mycosis fungoides: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1258-1265.	0.6	2
413	Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma. <i>PLoS ONE</i> , 2021, 16, e0248298.	1.1	14
414	Mycosis Fungoides in Children and Adolescents. <i>JAMA Dermatology</i> , 2021, 157, 431.	2.0	17
415	SÅ©zary Syndrome: a clinico-pathological study of 9 cases. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	1
416	Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience. <i>Dermatology and Therapy</i> , 2021, 11, 1085-1106.	1.4	16
417	CLINICAL, IMAGING AND PATHOLOGICAL ASPECTS OF MAMMARY LYMPHOMAS SECONDARY TO MALIGNANT T- CELL CUTANEOUS LYMPHOMAS. <i>Medico Oncology</i> , 2021, 2, 45-54.	0.3	0
418	Clinical characteristics and long-term outcomes of 97 Korean patients with mycosis fungoides. <i>International Journal of Dermatology</i> , 2021, 60, 1510-1519.	0.5	1
419	Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: A systematic review. <i>JAAD International</i> , 2021, 3, 26-41.	1.1	4
420	Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	2
421	Clinical characteristics and long-term outcome of 223 patients with mycosis fungoides at a single tertiary center in Korea: A 29-year review. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1275-1284.	0.6	4
422	Three-Dimensional Telomeric Fingerprint of Mycosis Fungoides and/or SÅ©zary Syndrome: A Pilot Study. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1598-1601.e4.	0.3	1
423	CD27 mRNA expression in mycosis fungoides. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.1	0
424	Cutaneous T cell lymphoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 61.	18.1	70
425	Targeting ITK signaling for TÀcell-mediated diseases. <i>IScience</i> , 2021, 24, 102842.	1.9	14
426	Alitretinoin in the treatment of cutaneous TÀcell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 7071-7078.	1.3	8

#	ARTICLE	IF	CITATIONS
427	Characteristics and outcomes of 727 patients with mycosis fungoides and SÅ©zary syndrome from a Brazilian cohort. <i>International Journal of Dermatology</i> , 2022, 61, 442-454.	0.5	5
428	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 733770.	1.3	13
429	Cutaneous Tâ€cell lymphomas: 2021 update on diagnosis, riskâ€stratification, and management. <i>American Journal of Hematology</i> , 2021, 96, 1313-1328.	2.0	21
430	Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network. <i>Dermatology</i> , 2022, 238, 498-506.	0.9	6
431	Mycosis fungoides und SÅ©zaryâ€Syndrom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1307-1335.	0.4	2
432	Mycosis fungoides and SÅ©zary syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1307-1334.	0.4	2
433	The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 919-932.	2.0	4
434	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 969-971.	0.6	4
435	Memorials and Mandates for Cutaneous Lymphomas. <i>Archives of Dermatology</i> , 2003, 139, 926-a-928.	1.7	6
436	Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma and Neutrophilic Dermatitis. <i>Archives of Dermatology</i> , 2005, 141, 353-356.	1.7	14
438	Combination Therapy for Cancer: Phototherapy and HDAC Inhibition. , 2014, , 445-470.		1
439	Cutaneous T-Cell Lymphomas: Mycosis Fungoides and SÅ©zary Syndrome. , 2013, , 287-329.		2
441	Primary Cutaneous T-Cell Lymphomas. , 2011, , 617-628.		3
442	Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. <i>JCI Insight</i> , 2019, 4, .	2.3	46
443	Immunopathogenesis and therapy of cutaneous T cell lymphoma. <i>Journal of Clinical Investigation</i> , 2005, 115, 798-812.	3.9	285
444	Review of the Treatment of Mycosis Fungoides and SÅ©zary Syndrome : A Stage-Based Approach. <i>International Journal of Health Sciences</i> , 2013, 7, 220-239.	0.4	22
445	Doxycycline is an NF-Î³B inhibitor that induces apoptotic cell death in malignant T-cells. <i>Oncotarget</i> , 2016, 7, 75954-75967.	0.8	35
446	Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. <i>Oncotarget</i> , 2019, 10, 3104-3113.	0.8	26

#	ARTICLE	IF	CITATIONS
447	Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. World Journal of Gastroenterology, 2016, 22, 3496-3501.	1.4	3
448	Approach to cutaneous lymphoid infiltrates: When to consider lymphoma?. Indian Journal of Dermatology, 2016, 61, 351.	0.1	20
449	Primary cutaneous lymphomas: A clinical and histological study of 99 cases in Isfahan, Iran. Journal of Research in Medical Sciences, 2015, 20, 827.	0.4	7
450	Management strategies for mycosis fungoides in India. Indian Journal of Dermatology, 2017, 62, 137.	0.1	2
451	Prognostic factors of patients with mycosis fungoides. Postepy Dermatologii I Alergologii, 2020, 37, 796-799.	0.4	12
452	Profile of mycosis fungoides in 43 Saudi patients. Annals of Saudi Medicine, 2012, 32, 283-287.	0.5	12
453	Cutaneous Lymphomas and Lymphocytic Infiltrates. , 2022, , 477-507.		0
454	An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway. Italian Journal of Dermatology and Venereology, 2021, 156, 413-421.	0.1	3
455	Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or SÃ©zary syndrome: a multicentre, phase 1 study. Lancet Haematology,the, 2021, 8, e808-e817.	2.2	42
457	Diagnosis and Treatment of SÃ©zary Syndrome. Internet Journal of Dermatology, 2004, 2, .	0.5	2
459	Sezary Syndrome. , 2004, , 43-47.		0
461	A 2008 nationwide survey on cutaneous lymphomas. Skin Cancer, 2009, 24, 192-198.	0.1	1
462	Light Therapies for Cutaneous T-Cell Lymphoma. , 2009, , 205-247.		0
463	Cutaneous infiltrates â€œ lymphomatous and leukemic. , 2010, , 971-1005.e30.		2
464	Cutaneous Lymphoma, Leukemia and Related Disorders. , 2010, , 197-231.		0
468	Cutaneous T-cell Lymphoma. , 2011, , 217-230.		0
469	Clinical features of patients with cutaneous lymphomas from Okayama University Hospital. Skin Cancer, 2011, 26, 191-196.	0.1	0
470	Hypopigmented Mycosis Fungoides in a 7-Year-Old Boy. Journal of Cosmetics Dermatological Sciences and Applications, 2012, 02, 64-67.	0.1	0

#	ARTICLE	IF	CITATIONS
472	Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma. , 2012, , 349-372.		0
473	Mature T-Cell and Natural Killer Cell Leukemias. , 2012, , 403-418.		0
474	Cutaneous T-Cell Lymphomas. , 2013, , 155-177.		0
475	Radiation Therapy of Cutaneous Lymphoma. , 2013, , 205-213.		0
476	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma. , 2014, , 2060-2075.e5.		0
477	Leukemia and Lymphoma. Part I. Mycosis Fungoides and SÅ©zary Syndrome: Using Molecular Tools to Aid in the Diagnosis, Staging, and Therapy for Mycosis Fungoides and SÅ©zary Syndrome. , 2014, , 133-165.		0
480	Cutaneous Lymphomas. , 2016, , 463-475.		0
481	Immunohistology and Molecular Studies of Cutaneous T-Cell Lymphomas and Mimics. , 2016, , 229-259.		0
482	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
483	Primary Cutaneous Lymphomas and Interferon Treatment. , 2017, 1, 001-010.		1
484	Cutaneous T-cell lymphoma in Saudi Arabia: retrospective single-center review. Annals of Saudi Medicine, 2017, 37, 212-215.	0.5	1
485	Common Presentations of Mycosis Fungoides in Pakistani Population: A Clinicopathological Study. Journal of the Dow University of Health Sciences, 2017, 11, 103-105.	0.2	0
486	Primary anaplastic large T-cell lymphoma â€œ a case report. Pediatria I Medycyna Rodzinna, 2017, 13, 540-546.	2.3	0
487	Clinical and Histopathological Spectrum of Mycosis Fungoides. Bahrain Medical Bulletin, 2018, 40, 103-107.	0.1	2
488	Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution. Radiation Oncology Journal, 2018, 36, 153-162.	0.7	1
489	Cutaneous T-Cell Lymphoma: Mycosis Fungoides and SÅ©zary Syndrome. , 2020, , 221-246.		0
490	Management experience of advanced-stage mycosis fungoides/SÅ©zary syndrome: a retrospective study from Spanish haematology referral units. European Journal of Dermatology, 2020, 30, 397-403.	0.3	0
491	Cutaneous Lymphomas and Lymphocytic Infiltrates. , 2020, , 1-31.		0

#	ARTICLE	IF	CITATIONS
492	Primary Extranodal Lymphomas of the GI Tract, Lung, CNS, and Skin with Common Mimics. , 2020, , 253-284.		0
494	T-Cell Non-Hodgkinâ€™s Lymphoma. , 2006, , 161-220.		3
497	Classification of Optical Images of Cervical Lymph Node Cells. IOP Conference Series: Materials Science and Engineering, 2020, 928, 072049.	0.3	0
498	41â€™Cutaneous infiltrates â€™ lymphomatous and leukemic. , 2010, , 851-881.		0
499	Review of the treatment of mycosis fungoides and SÃ©zary syndrome: A stage-based approach. International Journal of Health Sciences, 2013, 7, 220-39.	0.4	10
500	Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. Yale Journal of Biology and Medicine, 2020, 93, 111-121.	0.2	12
502	Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides. Cancers, 2021, 13, 5982.	1.7	7
503	Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas. Acta Dermato-Venereologica, 0, 102, adv00676.	0.6	1
504	The Use of Interferonâ€™2a as Monotherapy in Stage IB Patients with Mycosis Fungoides: A Retrospective Chart Review of Patient Outcomes. Dermatologic Therapy, 2022, , e15344.	0.8	1
505	Costâ€™effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. Journal of Comparative Effectiveness Research, 2022, 11, 193-202.	0.6	1
506	Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Advances, 2022, 6, 2290-2302.	2.5	6
507	Flow cytometry for the assessment of blood tumour burden in cutaneous Tâ€™cell lymphoma: towards a standardized approach. British Journal of Dermatology, 2022, 187, 21-28.	1.4	9
508	Gamma/Delta (Î³Î´) T Cells: The Role of the T-Cell Receptor in Diagnosis and Prognosis of Hematologic Malignancies. American Journal of Dermatopathology, 2022, 44, 237-248.	0.3	4
509	Strategies to Optimize Adherence in Patients with Mycosis Fungoides. Cells, 2022, 11, 113.	1.8	1
510	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. Journal of Palliative Medicine, 2022, 25, 958-963.	0.6	1
511	Mycosis fungoides and SÃ©zary syndrome. , 0, , 432-448.		0
514	Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.. Acta Dermato-Venereologica, 2022, , .	0.6	0
516	Subtlety of Granulomatous Mycosis Fungoides: A Retrospective Case Series Study and Proposal of Helpful Multimodal Diagnostic Approach With Literature Review. American Journal of Dermatopathology, 2022, 44, 559-567.	0.3	2

#	ARTICLE	IF	CITATIONS
517	Poor prognostic factors of SÅ©zary syndrome: A retrospective single-center study from Japan. <i>Journal of Cutaneous Immunology and Allergy</i> , 2022, 5, 125-132.	0.2	0
519	Current approaches to diagnostics of mycosis fungoides. <i>Vestnik Dermatologii I Venerologii</i> , 2010, 86, 16-22.	0.2	2
520	Assessment of prognostic predictive value at the mycosis fungoides. <i>Vestnik Dermatologii I Venerologii</i> , 2017, 93, 20-26.	0.2	0
522	Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study. <i>Leukemia and Lymphoma</i> , 0, , 1-8.	0.6	0
523	Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
524	Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and SÅ©zary syndrome. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 805-813.	0.6	2
525	Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis. <i>Cureus</i> , 2022, , .	0.2	0
526	Illness Perception Regarding Early-stage Mycosis Fungoides among Dermatologists: A Multi-centre Cross-sectional Study. <i>Acta Dermato-Venereologica</i> , 0, , .	0.6	1
527	Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. <i>Acta Ophthalmologica</i> , 2022, 100, 3-37.	0.6	2
529	Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2023, 98, 193-209.	2.0	12
530	Staging of Mycosis Fungoides and SÅ©zary Syndrome: Time for an Update?. <i>European Medical Journal Hematology</i> , 0, , 92-100.	0.0	5
531	EORTC QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and SÅ©zary syndrome: Real-world data in Spanish patients (MICADOS Study). , 2022, 1, 438-449.		0
532	Harnessing the immune system in the treatment of cutaneous T cell lymphomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
533	Cutaneous lymphomas – fast facts about an orphan disease – a short review. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
534	Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2023, 24, 153-164.	3.3	5
535	Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma. <i>JAMA Dermatology</i> , 2023, 159, 192.	2.0	2
536	Mycosis fungoides and SÅ©zary syndrome: clinical presentation, diagnosis, staging, and therapeutic management. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
537	Total Skin Treatment with Helical Arc Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4492.	1.8	2

#	ARTICLE	IF	CITATIONS
538	Mycosis fungoides: creation of a prospective, interdisciplinary and multicenter study in central Italy. Italian Journal of Dermatology and Venereology, 0, , .	0.1	0
539	New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications. Current Hematologic Malignancy Reports, 0, , .	1.2	1
540	Epidemiology and prognostic factors of 114 patients with mycosis fungoides in a Moroccan cohort: a 29-year review. Clinical and Experimental Medicine, 0, , .	1.9	0
544	Hematolymphoid Tumors. , 2023, , 453-496.		0
563	Indolente kutane T-Zell-Lymphome. , 2023, , 231-254.		0